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Missense mutations in the Leucine-Rich Repeat protein Kinase 2 (LRRK2) gene
are the most common genetic predisposition to develop Parkinson’s disease (PD)
(Farrer et al., 2005; Skipper et al., 2005; Di Fonzo et al., 2006; Healy et al.,
2008; Paisan-Ruiz et al., 2008; Lesage et al., 2010). LRRK2 is a large multi-domain
phosphoprotein with a GTPase domain and a serine/threonine protein kinase domain
whose activity is implicated in neuronal toxicity; however the precise mechanism is
unknown. LRRK2 autophosphorylates on several serine/threonine residues across the
enzyme and is found constitutively phosphorylated on Ser910, Ser935, Ser955, and
Ser973, which are proposed to be regulated by upstream kinases. Here we investigate
the phosphoregulation at these sites by analyzing the effects of disease-associated
mutations Arg1441Cys, Arg1441Gly, Ala1442Pro, Tyr1699Cys, Ile2012Thr, Gly2019Ser,
and Ile2020Thr. We also studied alanine substitutions of phosphosite serines 910,
935, 955, and 973 and specific LRRK2 inhibition on autophosphorylation of LRRK2
Ser1292, Thr1491, Thr2483 and phosphorylation at the cellular sites. We found that
mutants in the Roc-COR domains, including Arg1441Cys, Arg1441His, Ala1442Pro, and
Tyr1699Cys, can positively enhance LRRK2 kinase activity, while concomitantly inducing
the dephosphorylation of the cellular sites. Mutation of the cellular sites individually did
not affect LRRK2 intrinsic kinase activity; however, Ser910/935/955/973Ala mutations
trended toward increased kinase activity of LRRK2. Increased cAMP levels did not lead
to increased LRRK2 cellular site phosphorylation, 14-3-3 binding or kinase activity. In cells,
inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser1292 by Calyculin A
and Okadaic acid sensitive phosphatases, while the cellular sites are dephosphorylated
by Calyculin A sensitive phosphatases. These findings indicate that comparative analysis
of both Ser1292 and Ser910/935/955/973 phosphorylation sites will provide important and
distinct measures of LRRK2 kinase and biological activity in vitro and in vivo.
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INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative dis-
ease affecting 1–2% of the population over 65 years of age, with
approximately 60,000 newly diagnosed patients per year. It is esti-
mated that the prevalence of PD cases worldwide will double
by the year 2030 (Dorsey et al., 2007). The increasing disabil-
ity caused by the progression of disease burdens the patients,
their caregivers, as well as society. Hallmark clinical features of
PD include resting tremor, bradykinesia, postural instability and
rigidity. PD also exhibits a wide variety of non-motor features
such as autonomic dysfunction and dementia. Although the pat-
tern of neuronal loss in PD is well-characterized, the molecular
mechanisms of progressive cell death are still being elucidated.
The majority of PD patients suffer from idiopathic disease with
no clear etiology. However, approximately 5% of patients present
with familial PD (Zimprich et al., 2004; Di Fonzo et al., 2005,
2006; Farrer et al., 2005; Healy et al., 2008; Paisan-Ruiz et al.,
2008; Simon-Sanchez et al., 2009). Furthermore, exposure to a
number of environmental toxicants has been shown to increase
the risk of PD. Therefore, understanding the mechanisms of these
known causes and risks will likely lead to the development of
novel therapeutics, an unmet need.
Insights provided by understanding biochemical and cellu-
lar functions of the normal as well as mutated PD genes can
provide insights into the pathogenesis of both inherited and idio-
pathic PD, because mutations in the leucine-rich repeat kinase 2
gene (LRRK2) are a common cause of inherited and idiopathic
forms of PD. Genome-wide association studies have also identi-
fied LRRK2 as a risk factor for sporadic PD (Satake et al., 2009;
Simon-Sanchez et al., 2009; Ross et al., 2011; Lill et al., 2012).
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The informative nature of PD causing mutations on the molec-
ular basis of disease is demonstrated by LRRK2, because clinical
phenotypes of PD caused by LRRK2mutation are largely indistin-
guishable from idiopathic disease (Ishihara et al., 2006; Ross et al.,
2006; Haugarvoll et al., 2008; Haugarvoll and Wszolek, 2009),
however ascertainment of larger LRRK2 Gly2019Ser patient pop-
ulations will certainly define distinct clinical and pathologic fea-
tures of LRRK2 parkinsonism (Zimprich et al., 2004; Adams et al.,
2005; Whaley et al., 2006; Sossi et al., 2010).
LRRK2 encodes a large multi-domain protein with both a
GTPase and a kinase domain. The amino terminus [1–1287 aa]
is dispensable for kinase activity (Jaleel et al., 2007) but partic-
ipates in regulation of LRRK2. This region of LRRK2 contains
a phosphorylation cluster, an armadillo domain, an ankyrin
domain, and a leucine-rich repeat domain. The remaining pro-
tein [1335–2527aa] consists of the minimal catalytic fragment,
which includes the GTPase domain termed Ras of complex pro-
teins (Roc), followed by the C-terminal-of-Roc domain (COR),
which is contiguously connected to the N-terminus of the kinase
domain. The kinase domain bears similarity to mixed lineage
kinases, which are typically involved in kinase signaling cascades;
however no upstream or downstream kinases have been vali-
dated yet. The carboxy terminus contains a WD40 domain and
is essential for kinase activity. Deletion of the carboxy terminus
or substitution of the risk factor mutation Gly2385Arg decreases
kinase activity of LRRK2 (Jaleel et al., 2007; Greggio et al., 2008;
Jorgensen et al., 2009; Rudenko et al., 2012). Many of the LRRK2
substitutions described to be pathogenic are concentrated in
the catalytic tri-domain, including the Asn1437His, Arg1441Cys,
Arg1441Gly, Arg1441His, and Tyr1699Cys in the Roc and COR
domains, and Gly2019Ser and Ile2020Thr in the kinase domain
(Biskup and West, 2009). The Arg1628Pro risk factor muta-
tion falls within the COR domain (Ross et al., 2008; Tan et al.,
2008). The most common mutation in inherited and idiopathic
PD encodes Gly2019Ser, and is located in subdomain VII of the
kinase domain and has consistently been shown to increase kinase
activity 2–3 fold (Paisan-Ruiz et al., 2004; Zimprich et al., 2004;
West et al., 2005; Jaleel et al., 2007). Other pathogenic substi-
tutions, Arg1441Cys, Arg1441Gly, Arg1441His, Tyr1699Cys, and
Ile2020Thr, modestly increase kinase activity and GTPase activ-
ity (West et al., 2005, 2007; Greggio and Cookson, 2009; Nichols
et al., 2010; Webber et al., 2011).
LRRK2 kinase is itself a phosphoprotein that is regulated by
upstream kinases and autophosphorylation. LRRK2 autophos-
phorylation has been observed on more than 20 threonine and
serine residues with a preference for threonine (Kamikawaji et al.,
2009; Gloeckner et al., 2010; Li et al., 2010; Pungaliya et al.,
2010). Supplemental Table 1 gathers the reported autophos-
phorylation sites of LRRK2 from several publications. An Ala
substitution of Thr1503 decreases GTPase activity and kinase
activity (Webber et al., 2011). Autoregulation of Thr1348 or
Thr1349 affects GTP binding and kinase activity (Kamikawaji
et al., 2013). Autophosphorylation of Ser1292 has recently been
observed within cells as an indicator of LRRK2 kinase activity
through autophosphorylation (Sheng et al., 2012); however the
comparative utility to other autophosphorylation sites has yet to
be explored. In the absence of a validated downstream substrate
for LRRK2, autophosphorylation is a potential tool to under-
stand LRRK2 kinase activity in experimental or pathological
conditions.
A cluster of serines, including Ser910, Ser935, Ser955, and
Ser973, found preceding the namesake LRR domain, appears to
be constitutively phosphorylated on LRRK2. It has been pro-
posed that these sites are phosphorylated by kinases other than
LRRK2 itself (West et al., 2007; Gloeckner et al., 2010; Nichols
et al., 2010; Li et al., 2011; Doggett et al., 2012) and are referred
to as the cellular phosphorylation sites herein. These sites are
dynamically regulated, becoming rapidly dephosphorylated in
cells and tissues after inhibition of LRRK2 with small molecule
kinase inhibitors. This has been utilized as an indirect measure of
LRRK2 activity in cells and tissues by multiple groups. The phos-
phorylation of LRRK2 is also implicated in mutation induced
disease, as PD-associated mutations Asn1437His, Arg1441Cys,
Arg1441Gly, Arg1441His, Tyr1699Cys, and Ile2020Thr all show
decreased phosphorylation at the cellular phosphorylation sites
Ser910/935/955/973. Dephosphorylation of the cellular sites links
PD mutations and inhibition with similar molecular outcomes
such as relocalization to cytoplasmic accumulations and filamen-
tous skein like structures, loss of 14-3-3 binding and increased
binding of PP1α (Greggio et al., 2006; Alegre-Abarrategui et al.,
2009; Nichols et al., 2010; Kett et al., 2011; Lobbestael et al., 2013).
LRRK2 activity is regulated by inputs from other domains;
these could be intramolecular or intermolecular via domain-
domain interactions or oligomerization. The GTPase activity of
Roc influences kinase activity of the kinase domain, while the
carboxy terminus is also necessary for kinase activity. The PD-
associated mutation Gly2385Arg or deletion of only the last
seven amino acids in the C-terminus of LRRK2 leads to down-
regulation of kinase activity. PD-associated mutations of the
Roc domain [Arg1441Cys/Arg1441Gly/Arg1441His] or the COR
domain [Tyr1699Cys], which showed reduced GTPase activity
and/or impaired dimerization, also impact kinase activity of
LRRK2. The kinase domain is thought to signal back to the
amino terminus via a feedback phosphorylationmechanism of an
intermediate kinase(s). Analysis of autophosphorylation mutants
can help determine how each domain can regulate activity of
LRRK2. Herein, we elucidate differential effects of PD muta-
tions in the Roc-COR, kinase, and carboxy terminus of LRRK2
on the autophosphorylation at Ser1292, Thr1491, and Thr2483
with respect to cellular phosphorylation at Ser910/935/955/973.
These outputs were also analyzed in phosphosite mutations of
the amino terminus. We found that Ser1292 autophosphoryla-
tion is effective at detecting kinase activity in cells and reveals
increased kinase activity of a heterozygous Gly2019Ser muta-
tion in patient derived, Epstein-Barr virus (EBV) immortalized
lymphoblasts. However, Ser1292 autophosphorylation is inversely
regulated with the cellular site phosphorylation readouts in sev-
eral PD associated mutations. We clearly show that Roc-COR PD
mutations increase kinase activity and also decreased phospho-
rylation of the cellular sites. Alanine substitutions of Ser1292,
Thr1491, Thr2483, Ser910/Ser935, Ser955, or Ser973 did not
decrease LRRK2 kinase activity, nor did Ser1292, Thr1491, and
Thr2483 to Ala substitutions decrease cellular site phosphoryla-
tion. We found that increased cyclic adenosine-monophosphate
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(cAMP) does not lead to increased phosphorylation of Ser1292,
Ser910, Ser935, Ser 955, or Ser973 in HEK293 cells. Additionally,
we found that Ser1292 is regulated by Okadaic acid and Calyculin
A sensitive phosphatases in contrast to the cellular sites which are
only subject to regulation by Calyculin A sensitive phosphatases.
MATERIALS AND METHODS
REAGENTS AND GENERAL PROCEDURES
Tissue culture reagents were from Life Technologies or Thermo
Scientific. The Flp-in T-REx system was from Invitrogen and sta-
ble cell lines were generated as per manufacturer instructions
by selection with hygromycin as has been described previously
(Nichols et al., 2010; Doggett et al., 2012). Restriction enzyme
digests, DNA ligations, and other recombinant DNA proce-
dures were performed using standard protocols with Fermentas
enzymes. DNA constructs used for transfection were purified
from Escherichia coli DH5a using Qiagen plasmid Maxi kits or
Invitrogen Maxi pep kits according to the manufacturer’s proto-
col. All DNA constructs and DNA transfections were performed
using the polyethylenimine method according to Reed et al.
(2006).
All DNA constructs used for transfections were provided
by Dr. Dario Alessi (MRC-PPU, Dundee University, Dundee
Scotland), except the autophosphorylation plasmids (FLAG-
Thr1491, FLAG-Th2483, FLAG-S1292). These plasmids and the
alanine substitutionmutants of the autophosphorylationmutants
were sub-cloned from the corresponding pCMV5-FLAG con-
structs. All mutagenesis experiments were carried out using the
GeneArt site-directed mutagenesis kit (Life Technologies). All
DNA constructs were verified by DNA sequencing, performed by
Sequetech, Mountain View, CA. Full length amino terminal FLAG
tagged LRRK2 was expressed by expressed by BacMam infection
of HEK293 cells and purified by immunoaffinity chromatogra-
phy with anti-FLAG M2. Inhibitor GNE1023 was described in
Sheng et al. (2012) and synthesized at Genentech, LRRK2-IN1
was purchased from Tocris and Forskolin and IBMX were from
Sigma.
BUFFERS
Lysis Buffer contained 50mM Tris/HCl, pH 7.4, 1mM EGTA,
1mM EDTA, 1mM sodium orthovanadate, 10mM sodium β-
glycerophosphate, 50mM NaF, 5mM sodium pyrophosphate,
0.27M sucrose, 1mM Benzamidine, and 1mM phenylmethane-
sulphonylfluoride (PMSF) and was supplemented with 1% Triton
X-100. Buffer A contained 50mMTris/HCl, pH 7.4, 50mMNaCl,
0.1mM EGTA, and 0.27M sucrose. Kinase buffer was 50mMTris
7.4, 0.1mM EGTA.
CELL CULTURE, TREATMENTS AND CELL LYSIS
HEK-293 cells were cultured in Dulbecco’s Modified Eagle’s
medium supplemented with 10% FBS, 2mM glutamine and 1×
antimycotic/antibiotic solution. HEK-293 T-REx cell lines were
cultured in DMEM supplemented with 10% FBS and 2mM glu-
tamine, 1× antimycotic/antibiotic and 15μg/ml Blasticidin and
100μg/ml hygromycin. Cell transfections were performed by the
polyethyleniminemethod (Reed et al., 2006). T-REx cultures were
induced to express the indicated protein by inclusion of 1μg/ml
doxycycline in the culture medium for 24 h. Human lung alve-
olar epithelial A549 cells were cultured in Ham’s F-12 (Kaighn’s)
with 10% FBS, 1× antimycotic/antibiotic. After the indicated cul-
ture conditions, cells were washed once with PBS and lysed in situ
with 1.0ml of lysis buffer per 15 cm dish on ice, then centrifuged
at 15,000 × g at 4◦C for 15min. HEK-293 cells transfected with
LRRK2 WT and mutant plasmids were lysed 48 h after transfec-
tion. Lymphoblastoid cell lines generated by EBV transformation
of B lymphocytes were obtained fromCoriell Institute forMedical
Research. Cell line ND00075 (+/Gly2019Ser) is derived from
a donor heterozygous for a G > A transition in exon 42 of
LRRK2. Cell line ND03335 is an asymptomatic donor. Human
lymphoblastoid cells were maintained in RPMI 1640 with 10%
FBS, 2mM glutamine, 1× antimycotic/antibiotic and were main-
tained at cell density of 0.3 × 106–2 × 106 cells per ml. Protein
concentrations were determined using the Bradford method with
BSA as the standard.
KINASE ASSAYS
Kinase assays were set up in a total volume of 50μl with recombi-
nant LRRK2 or immunoprecipitated LRRK2 as a source of kinase
in 50mM Tris/HCI, pH 7.5, 0.1mM EGTA, 10mM MgCl2, and
0.1mM (γ-32P) ATP (500–600 c.p.m/pmol) in the presence of
200μM LRRKtide peptide substrate. Reactions were incubated
at 30◦C for the indicated times. Reactions were terminated by
addition of LDS protein loading buffer or applying 40μl of the
reaction mixture on to P81 phosphocellulose paper and immer-
sion in 50mM phosphoric acid. After extensive washing, reaction
products were quantified by Cerenkov counting. For autophos-
phorylation assays, 140 nm of FLAG-LRRK2 was incubated at
30◦C for the indicated times in the presence of 10mM MgCl2
and 0.1mM ATP and stopped by the addition of an equal vol-
ume of ice-cold 100mM EDTA. Reaction products were spotted
on nitrocellulose and immunoblotted with FLAG and autophos-
phorylation site antibodies.
LRRK2 IMMUNOPRECIPITATION ASSAYS
Cell lysates were prepared in lysis buffer (1.0ml per 15 cm
dish) and subjected to immunoprecipitation with anti-FLAG M2
agarose or GFP-Trap A beads (Chromotek) at for 1 h. Beads were
washed twice with Lysis Buffer supplemented with 300mMNaCl,
then twice with Buffer A. Immune complexes were either used in
kinase assays or incubated at 70◦C for 10min, passed through a
Spin-X column (Corning) to separate the eluate from the beads,
then boiled in LDS sample buffer. LRRK2 transfectedHEK293 cell
lysates were subjected to immunoprecipitation as with GFP-Trap
beads. For endogenous immunoprecipitation assays, LRRK2 was
immunoprecipitated using Anti-LRRK2 (UDD3, Abcam) non-
covalently conjugated to protein-A sepharose (1μg antibody: 1μl
bead) and analyzed by immunoblotting.
STATISTICAL ANALYSIS
For quantification of phosphorylation levels, LRRK2 protein lev-
els were normalized for expression and to the control experimen-
tal condition. Statistical analysis was done using GraphPad Prism
6. One-sample t-tests using the hypothetical value of 1 for com-
parison and standard One-Way ANOVA tests were performed
Frontiers in Molecular Neuroscience www.frontiersin.org June 2014 | Volume 7 | Article 54 | 3
Reynolds et al. LRRK2 phosphoregulation
with either the Dunnett correction for comparison with a single
mean or the Tukey–Kramer correction if every mean is compared
individually. P-values are designated as ∗p ≤ 0.05.
RESULTS
DIFFERENTIAL PHOSPHO-REGULATION OF LRRK2 IN PD ASSOCIATED
MUTANTS
In vitro characterization of LRRK2 autophosphorylation in wild type
and PD-associated LRRK2 mutants
LRRK2 phosphorylation is a heavily studied aspect of the
enzyme’s regulation. LRRK2 phosphosites have been identified
from in vitro autophosphorylation kinase assays and from enzyme
isolated from cells. LRRK2 contains sites of autophosphoryla-
tion and also sites that are modified by upstream kinases. We
first wished to test the in vitro utility of the autophosphoryla-
tion site antibodies as indicators of LRRK2 kinase activity in
an isolated system, to which we could compare the effects we
observe in cellular studies. To detect LRRK2 phosphorylation, we
utilized a series of rabbit monoclonal antibodies (anti-pSer910,
anti-pSer935, anti-pSer955, anti-pSer973, anti-pThr1491, anti-
pThr2483), generated by the Michael J. Fox Foundation and
characterized by their Antibodies Working Group, and anti-
pSer1292 (generously provided by Genentech), and a rabbit
polyclonal anti-pThr1503 [kind gift of Dr. Andrew West, UAB
(Webber et al., 2011)]. We verified specificity for the phospho-
rylation sites with Ser/Thr to alanine mutants, Supplemental
Figure 1 and observed no ab initio phosphorylation of Thr1491
or Thr2483. We also observed that Ala substitutions at these
sites did not negatively impact autophosphorylation at any of
the other sites. We next employed full length recombinant
LRRK2 [wild-type, Gly2019Ser, Arg1441Cys, and Asp1994Ala]
(LifeTechnologies), which are approximately 80% pure as indi-
cated by colloidal blue staining, Figure 1A. Immunoblot analysis
of these preparations with anti phospho-Ser910, 935, 955, and
973 antibodies, revealed that phosphorylation of the cellular sites
is maintained throughout the purification process and is simi-
lar between LRRK2 wild-type and Gly2019Ser. We observed no
decrement in the cellular phosphorylation sites of the Arg1441Cys
mutation, which has been previously described for Arg1441Gly,
Arg1441His substitutions at this residue (Nichols et al., 2010;
Doggett et al., 2012). Interestingly, only phosphorylation of the
Ser1292 autophosphorylation site was detected in these recom-
binant protein preparations, as we could not detect ab initio
phosphorylation of Thr1491 or Thr2483. The PD causing muta-
tions Gly2019Ser and Arg1441Cys exhibited enhanced Ser1292
phosphorylation compared to wild-type, and kinase inactive
LRRK2 is not modified at Ser1292 whereas the cellular sites are,
Figure 1B.
We characterized the LRRKtide kinase activity of the full
LRRK2 length proteins in order to correlate autophosphoryla-
tion activity with substrate phosphorylation, Figure 1C. We con-
firmed that Gly2019Ser mutation exhibited approximately a 2.5
fold increase in specific activity (determined from the linear time
points of the reaction) and also observed that the Arg1441Cys
mutation increases kinase activity against a peptide substrate
approximately 20% over wild-type LRRK2 (Jaleel et al., 2007;
Webber et al., 2011), but not at levels equal to Gly2019Ser.
We next compared LRRK2 autophosphorylation at Ser1292
in the amino terminal domain, at Thr1491 and Thr1503 in the
central (Roc-COR) region and Thr2483 within the carboxy termi-
nus. We performed in vitro autophosphorylation assays with full
length LRRK2 in the absence of a substrate and analyzed the abil-
ity of the LRRK2 protein to phosphorylate itself over a time course
of 60min using immunoblot of the autophosphorylation sites as a
readout. The reaction products were analyzed with anti-pSer1292,
pThr1491, pThr1503, and pThr2483 antibodies and quantitated
with Odyssey Software (LiCor).
The autophosphorylation sites on LRRK2 were fully modi-
fied and reached maximal detection by 20min, showing similar
in vitro kinetics of LRRKtide phosphorylation, Figures 1C–G.
All antibodies detected a twofold increase in autophosphory-
lation in the Gly2019Ser mutant and the autophosphorylation
activity of the Arg1441Cys mutant is increased relative to wild-
type for each antibody tested. Since Ser1292 is phosphorylated
at the beginning of the reaction, Gly2019Ser and Arg1441Cys
time zero phosphorylation levels are not zero. In contrast to the
autophosphorylation sites, the cellular LRRK2 signals did not
increase throughout the kinase reaction (data not shown), sug-
gesting that these sites have reached their limit of phosphorylation
and further suggesting these are not autophosphorylation sites.
Autophosphorylation of LRRK2 and LRRKtide phosphorylation
are comparable indicators of LRRK2 kinase activity.
Reciprocal regulation of the cellular sites and LRRK2
autophosphorylation
Phosphorylation of the LRRK2 cellular sites is disrupted in the PD
mutations Asn1437His, Arg1441Gly, Arg1441His, Tyr1699Cys,
and Ile2020Thr (Nichols et al., 2010; Li et al., 2011; Doggett et al.,
2012; Lobbestael et al., 2013), while at the same time exhibiting
small or enhanced levels of kinase activity (Sheng et al., 2012). To
characterize and further understand this dichotomy, we sought
to directly compare phosphorylation of Serines910, 935, 955, and
973 with the three autophosphorylation sites Ser1292, Thr1491,
and Thr2483 on LRRK2.
We compared the basal phosphorylation in cells to the
in vitro autophosphorylation of PD mutated LRRK2 using anti-
GFP immunoprecipitates from HEK293 T-REx cells express-
ing GFP-LRRK2 WT, Arg1441Cys, Arg1441Gly, Ala1442Pro,
Tyr1699Cys, Ile2012Thr, Gly2019Ser, and Ile2020Thr in a tetracy-
cline inducible manner, Figure 2A. Ala1442Pro is an uncommon
mutation (Huang et al., 2007) and has been shown to illicit similar
lack of phosphorylation of LRRK2 at the cellular sites and form
cytoplasmic accumulations (Greene et al., 2014). Tyr1699Cys is
located in the COR domain and also is dephosphorylated at
the cellular sites and forms cytoplasmic inclusions, and may
impact Roc GTPase activity via decreasing self-association or
directly on GTPase activity (Daniels et al., 2011). This mutant
will allow us to directly assess the in cis influence of Roc-COR
domain mutations on the intrinsic kinase activity of LRRK2.
The various LRRK2 PD associated mutations were incubated
in the presence or absence of Mg2+/ATP, where reactions per-
formed in the absence of ATP are representative of the basal
state of modification in cells. Reaction products were analyzed by
immunoblot with cellular site antibodies and antibodies against
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FIGURE 1 | Detection of autophosphorylation and cellular
phosphorylation sites on recombinant LRRK2. The indicated
full-length recombinant LRRK2 proteins were resolved by SDS-PAGE
and stained with either (A) Colloidal Blue to quantify relative protein
levels or (B) the indicated phospho-specific antibodies. (C) 14 nM of
recombinant wild type LRRK2 (WT) or mutant LRRK2 [Asp1994Ala,
Gly2019Ser, Arg1441Cys] in vitro kinase activity was measured
against LRRKtide. Incorporated 32P was assessed by Cerenkov
counting and results are representative of three independent
experiments. Error bars represent mean ± SD. (D–G) 140 nM
recombinant LRRK2 was incubated with Mg2+/ATP over a timecourse
of 60min where reaction aliquots were stopped by 1:1 (vol:vol)
dilution in 200mM EDTA and analyzed by dot-blot immunoblot with
rabbit monoclonal anti-phospho-Ser1292 (αpS1292), anti-phospho-Thr2483
(αpThr2483), anti-phospho-Thr1491 (αpThr1491) and rabbit polyclonal
anti-phospho-Thr1503 antibodies. Results are representative of three
independent experiments performed in duplicate and blotted in
duplicate. Error bars represent mean ± SD.
Thr1491, Thr2483, and Ser1292; data are presented as quanti-
fied LiCor Odyssey values of phospho-signal/total protein set to
WT in Supplemental Figure 2. The basal phosphorylation state
in the PD-associated mutants showed that Ser1292 and cellu-
lar sites (Ser935, 955, and 973) are not uniformly regulated. For
mutants Arg1441Cys, Arg1441Gly, Ala1442Pro, and Tyr1699Cys
we found that LRRK2 is dephosphorylated at the cellular sites, but
is hyperphosphorylated at Ser1292. But like Arg1441Cys behaved
in vitro, after incubation with ATP, Ser1292 phosphorylation was
comparable with WT LRRK2, leaving Gly2019Ser and Y1699C as
the only mutants that can incorporate significantly more phos-
phate at this site from all the mutants tested here. Threonines
1491 and 2483 were evaluated in the presence of ATP and we
found that Thr1491 revealed significant increase in modification
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FIGURE 2 | Comparison of autophosphorylation and cellular
phosphorylation sites in PD-associated mutants. Stable-inducible HEK
293 T-REx cell lines harboring the indicated forms of LRRK2 were incubated
for 48 h with 1μg/ml doxycycline to induce expression. The GFP-LRRK2 WT
line was treated with 1μM GNE1023 for 90min, before
immunoprecipitation-kinase assay using GFP beads, in the presence (+) or
absence (−) of ATP. LiCor immunoblot analysis of (A) WT and PD
associated mutants of LRRK2 and (B) WT and cellular phosphorylation
mutants. Reaction products were probed with rabbit monoclonal
anti-phospho-Ser935 (αpS935), anti-phospho-Ser955 (αpS955),
anti-phospho-Ser973 (αp973), anti-phospho-Ser1292 (αpS1292),
anti-phospho-Thr2483 (αpThr2483), anti-phospho-Thr1491 (αpThr1491).
Blots were probed with anti-GFP (αGFP) for total protein control.
Phosphorylation levels are quantitated in Supplemental Figure 2.
from the Gly2019Ser mutation, while Thr2483 revealed signifi-
cant increased kinase activity from Arg1441Gly, and Gly2019Ser.
Both Ile2020Thr and Ile2012Thr mutations reduced the basal
level of Ser1292 and autophosphorylation activity similar to activ-
ity determinations using LRRKtide and Nictide (Jaleel et al., 2007;
Nichols et al., 2009). The Ala1442Pro mutant revealed reduced
levels of phosphorylation at Thr1491 and Ser1292.
Evidence that autophosphorylation and cellular phosphorylation
sites are independently regulated, but dependent on LRRK2 kinase
activity
Several LRRK2 PD mutations that have exhibited increased
Ser1292 phosphorylation (Arg1441Cys, Arg1441Gly,
Tyr1699Cys) were dephosphorylated at the cellular sites.
Arg1441Gly, Arg1441Cys, and Tyr1699Cys mutants have
been shown to form aggregates, which are also seen in the
Ser910/935Ala mutant, due to the loss of phospho-dependent
interaction with 14-3-3 proteins. We wanted to determine if the
Roc-COR mutations effect on kinase activity could be correlated
with the loss of cellular phosphorylation. Previous data and
Figure 2A indicate that Roc-COR mutations act across the
enzyme intramolecularly to the kinase domain to activate the
kinase, but also intermolecularly inducing dephosphorylation
of the amino terminal cellular sites. We hypothesized that the
increase in 1292 phosphorylation in these mutants in cells could
be due to intramolecular effects of the amino terminus on the
kinase domain. An alternate explanation is there could be an
increase in the local concentration or compaction of dephos-
phorylated LRRK2 in cytoplasmic inclusions that caused more
autophosphorylation or less dephosphorylation. We tested these
hypotheses on isolated GFP-LRRK2 from HEK293 T-REx cells
with stable and inducible expression of LRRK2 cellular phospho-
site to alanine mutations [Ser910/935Ala, Ser955Ala, Ser973Ala,
and a combination mutant Ser910/935/955/973Ala], Figure 2B,
which mimic dephosphorylation of the cellular sites by inhibition
or mutation and analyzed LRRK2 phosphorylation after incuba-
tion with and without Mg2+/ATP in an in vitro kinase assay.
As with the recombinant LRRK2 preparations, we found
that autophosphorylation of Thr1491 and Thr2483 was only
detected after incubation of LRRK2 with Mg2+/ATP in vitro,
in immune-complex kinase assays, Figure 2B and quantitated in
Supplemental Figure 2.Mutation of cellular phosphorylation sites
[Ser910/935Ala, Ser955Ala, and Ser973Ala] individually had no
significant effect on the autophosphorylation of Thr1491 and
Thr2483 in the presence of ATP, nor on Ser1292 in cells or
in vitro in the presence of ATP, Figure 2B. However, in the com-
bination mutant, all autophosphorylation sites trended toward
increased kinase activity, (pSer1292 p = 0.066; pThr1491 p =
0.097; pThr2483 p = 0.055). Supplemental Figure 1 also indicates
that reciprocal mutation of the autophosphorylation sites does
not negatively affect phosphorylation at the cellular sites.
ANALYSIS OF SERINES 910/935/955/973 AND Ser1292
DEPHOSPHORYLATION
Serines 910/935/955/973 and Ser1292 are dephosphorylated after
inhibition of LRRK2
In cells, phosphorylation of the cellular sites and autophospho-
rylation of Ser1292 is dependent on kinase activity of LRRK2.
Inhibition of WT LRRK2 with a LRRK2 inhibitor induces the
rapid dephosphorylation at the cellular phosphorylation sites
(Ser910, 935, 955, 973) and the 1292 site (–ATP lane), Figure 2.
To compare the sensitivity of dephosphorylation on serine 1292
vs. the various cellular sites, which can be used to indicate activ-
ity of LRRK2, we subjected cells expressing LRRK2 [Gly2019Ser]
to a dose response of two structurally distinct LRRK2 inhibitors,
LRRK2-IN1 (Deng et al., 2011) and GNE1023 (Estrada et al.,
2012; Sheng et al., 2012) for 90min. Cell lysates were analyzed
by immunoblot with antibodies against Ser910, 935, 955, 973
in order to compare the phosphorylation status at each site,
LiCor quantitation of immunoblots in Supplemental Figure 3.
Both inhibitors induced a dose-dependent dephosphorylation of
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LRRK2 at the cellular sites and 1292 site, Supplementary Table 1.
We find that the shift in biochemical IC50 to cellular IC50 was on
the same order of magnitude for Ser1292 compared to the cellu-
lar Ser935, Ser955, and Ser973 sites. We also found that LRRK2
Ala2016Thr mutation blocks the induced dephosphorylation at
both types of sites showing that direct inhibition of LRRK2 is
required for both dephosphorylation of the autophosphorylation
site Ser1292 and the cellular phosphorylation sites, Supplemental
Figure 3F. These data indicate that the four cellular phospho-
rylation sites are effective, though indirect measures of LRRK2
inhibition compared to the direct detection of in vivo LRRK2
kinase activity with pSer1292.
Comparison of Ser1292 and cellular site dephosphorylation in
Parkinson’s disease patient-derived lymphoblastoid cells
Since many mutations of LRRK2 increase the kinase activity of
the enzyme, LRRK2 inhibitors could serve as a potential preventa-
tive or disease modifying drug. In the absence of reliable measures
of drug-target engagement such as LRRK2 inhibitor PET ligands,
peripheral markers of LRRK2 inhibition could serve as surro-
gate markers of LRRK2 inhibition in patients. LRRK2 is highly
expressed in immune cells and we sought to compare the effec-
tiveness of cellular site and autophosphorylation site antibodies
as indicators of LRRK2 activity in EBV transformed lymphoblasts
from a control and a PD affected patient heterozygous for
Gly2019Ser missense mutation. The cells were treated for 90min
with 2μM GNE1023 before endogenous LRRK2 was immuno-
precipitated and equal amounts of protein were immunoblotted
for pSer1292 and Ser935, Ser955, and Ser973 cellular phosphosite
antibodies, Figure 3B. Similar levels of LRRK2 were found in the
wild type and Gly2019Ser cell line. We were able to detect Ser1292
in the WT lymphoblasts (arrow in Figure 3B), with an increase
in pSer1292 observed from the heterozygous Gly2019Ser cells,
Figure 3. The increase in Ser1292 signal therefore reveals upreg-
ulated LRRK2 activity in Gly2019Ser lymphoblasts. Furthermore,
the cells responded to treatment with GNE1023 in culture, show-
ing dephosphorylation at both autophosphorylation and cellular
sites, further validating the potential of these sites as potential
pharmacodynamic markers of LRRK2 inhibition in patients.
cAMP does not increase LRRK2 phosphorylation in cells of kidney
or lung origin
One model of LRRK2 regulation places the kinase domain
downstream of the GTPase domain. In support of this, muta-
tional analysis of the GTPase domain at Arg1441 appears to
prolong the active state of LRRK2 by increasing its affinity
for GTP and decreasing GTPase activity (Liao et al., 2014).
Tyr1699Cys also decreases GTPase activity which could also lead
to increased kinase activity (Daniels et al., 2011). We demon-
strate in Figures 1–3, that these Roc-COR mutations increase
kinase activity while strongly promoting dephosphorylation of
the cellular sites. An alternate defect in LRRK2 regulation by
Arg1441Gly was recently reported in Muda et al. (2014), where
Ser1444 has been proposed as a new site of PKA phosphorylation
that is required for 14-3-3 binding. In vitro Ser1444 phosphoryla-
tion and 14-3-3 binding are disrupted in the Arg1441Gly mutant,
resulting in increased kinase activity in this model. LRRK2 was
also found to intersect with PKA function by downregulating
PKA activity in striatal projection neurons, where loss of LRRK2
or expression of a Arg1441Cys mutation leads to increased GluR1
and cofillin phosphorylation (Parisiadou et al., 2014). We there-
fore asked if activation of PKA, through modulating cAMP levels,
changes LRRK2 phosphorylation at the cellular sites or activity
in cells assayed through Ser1292. If PKA downregulates LRRK2
kinase activity and directly phosphorylates the cellular sites, then
increasing PKA activity in cells would lead to decreased autophos-
phorylation of Ser1292 and increased phosphorylation at the
cellular sites. We expressed GFP-LRRK2 WT, KD, Gly2019Ser,
Arg1441Gly, Tyr1699Cys, Ser910/935Ala in HEK293 T-REx cells
for 1 day, followed by 18 h of serum starvation then stimulation
with Forskolin and IBMX for 30min followed by immunoblot
analysis Figure 4. These compounds increase cyclic AMP lev-
els and block phosphodiesterase activity yielding increased PKA
activity respectively, as indicated by increased PKA substrate
antibody signal on whole cell lysates, Figure 4 quantitation in
Figure 4A and immunoblot in Figure 4B. We found that all
the cellular phosphorylation sites were significantly diminished
by approximately 20% in a PKA activated environment and
pSer1292 was not significantly changed. These data are in agree-
ment with a recent report by Hermanson et al. (2012), which
analyzed pSer935 levels following treatments with various LRRK2
inhibitors. In that report, PKA inhibitor H89 was not effective or
had high cellular IC50 values compared other LRRK2 inhibitors
in unstimulated HEK293 and U20S and SHSY5Y cells.
According to the model presented in Muda et al. (2014),
PKA stimulated 14-3-3 binding negatively regulates LRRK2 activ-
ity and in the absence of this interaction activity would be
increased. Thus, when PKA is activated, LRRK2 activity would
be repressed. With the ability to assess LRRK2 activity directly in
cells, we next asked if LRRK2 mutated in the Roc [Arg1441Gly]
and COR [Tyr1699Cys] mutations, which would be deficient
in cellular site phosphorylation, could regain 14-3-3 binding
after Forskolin/IBMX treatment. The Ser910/935Ala mutant was
included to detect PKA induced 14-3-3 binding independent of
these sites. We observed no significant change in vivo LRRK2
kinase activity as indicated by Ser1292 phosphorylation after PKA
stimulation, Figure 4B. This is consistent with previous reports
that demonstrate the 14-3-3 interaction with LRRK2 is abolished
by Ala substitution of Serines 910 and 935 in unstimulated condi-
tions (Nichols et al., 2010). FSK/IBMX treatment also decreased
the amount of LRRK2-14-3-3 complex in cells as demonstrated
by co-immunoprecipitation, Figure 4C.
We wanted to confirm the effects of IBMX/FSK treatment in
an additional cell line. LRRK2 knockout rodents develop abnor-
malities of the kidney and lung, showing accumulation of mem-
branous materials and disruption of autophagy (Herzig et al.,
2011; Baptista et al., 2013). A549 lung alveolar epithelial cells
express significant amounts of endogenous LRRK2 (Lobbestael
et al., 2013), and we used this cell system as a pertinent model of
endogenous LRRK2 regulation. LRRK2 was immunoprecipitated
from A549 cells after stimulation with IBMX/FSK, Figure 4D.
Similar to the GFP expression system, we also observed a decrease
in LRRK2 phosphorylation at the cellular sites. We were not able
to detect a distinct pSer1292 on the endogenous LRRK2. Based
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FIGURE 3 | Comparative analysis of inhibitor induced
dephosphorylation for Ser1292 and cellular phosphorylation sites
after kinase inhibition. (A) HEK 293 T-REx cells stably expressing
GFP-LRRK2-Gly2019Ser were treated with DMSO or increasing
concentrations of GNE1023 or LRRK2-IN1 for 90min. Cell lysates were
co-immunoblotted for GFP and anti-phospho-Ser935 (αpS935),
anti-phospho-Ser955 (αpS955), anti-phospho-Ser973 (αp973),
anti-phospho-Ser1292 (αpS1292). IC50 values were calculated using
non-linear regression analysis using GraphPad Prism 6.0. (B) Detection
of endogenous pSer1292 in human lymphocytes. Cultures of control
donor and +/Gly2019Ser donor lymphoblasts were treated with
GNE1023 for 90min. Endogenous LRRK2 was immunoprecipitated and
subjected to immunoblot analysis with the indicated phospho-antibodies.
Blots were co-probed with N241 monoclonal antibody to detect total
endogenous protein. Arrowhead indicates non-specific band and arrow
indicates LRRK2.
on these results, the activation of LRRK2 by PKA may be specific
to COS cells, which were used in Muda et al. Our experiments
didn’t demonstrate a role for PKA in LRRK2 phosphorylation or
autophosphorylation. In fact cAMP stimulation downregulated
LRRK2 phosphorylation and suggested that a phosphatase may
be activated in HEK293 and A549 cells.
Chemical analysis of Ser910/935/955/973 and Ser1292 phosphatases
Phosphorylation of LRRK2 at the cellular sites and Ser1292 are
efficient, although distinct indicators of LRRK2 kinase activ-
ity. The use of cellular phosphorylation sites as readouts of
kinase activity in the Arg1441Gly, Arg1441Cys, Arg1441His, or
Tyr1699Cys mutants is complicated by the increased interaction
with phosphatase PP1, which leads to dephosphorylation of the
cellular sites and reduced 14-3-3 interaction similar to treatment
with LRRK2 inhibitors. Blocking PP1 activity with Calyculin
A or expression of inhibitor proteins suppressed the induced
dephosphorylation and inclusion body formation from kinase
inhibition or PD mutations (Lobbestael et al., 2013). We assayed
the sensitivity of Ser1292 to Calyculin A (CA) and Okadaic acid
(OA), inhibitors of PP1 and PP2 respectively, in the context
of LRRK2 inhibition and Arg1441Gly mutation, Figure 5. We
expressed GFP-LRRK2 Gly2019Ser and Arg1441Gly in HEK293
T-REx cells in a doxycycline inducible manner for 1 day and
treated cells with OA, CA, with and without GNE1023. We found
that unlike Ser910/935/955/973, Ser1292 phosphorylation is sen-
sitive to both CA and OA. Similar to previous reports, cellular
site phosphorylation is rescued after inhibition of CA sensi-
tive phosphatases, but not OA ones. Ser1292 phosphorylation is
enhanced by both CA and OA treatment, indicating that LRRK2
autophosphorylation is regulated by both PP1 and PP2 type
phosphatases. Unlike the cellular phosphorylation sites, Ser1292
phosphorylation is not restored by phosphatase inhibition after
LRRK2 inhibition, confirming that Ser1292 is an autophospho-
rylation site and the cellular sites are regulated by upstream
kinases.
DISCUSSION
Understanding how PD mutations in LRRK2 affect its biochem-
ical properties and functional activities is essential to elucidation
of how LRRK2 dysfunction causes neurodegenerative disease. The
neurotoxicity of LRRK2 is connected with its kinase activity and
mutants that increase kinase activity may be more pathogenic
in patients. The GTPase and COR domains feed into the kinase
domain and participate in LRRK2 regulation via intramolecu-
lar and intermolecular mechanisms (Biosa et al., 2013). By using
mutations across the enzyme, we derive a better understanding
of regulation of LRRK2 by itself and upstream enzymes. In this
study, we used in vitro assays and expression systems to char-
acterize the interplay of PD mutations and Ser910/935/955/973
phosphorylation and LRRK2 kinase activity that can be neuro-
toxic.
To gain insight into the effects of mutations in the Roc-COR
and kinase domains on LRRK2 catalytic activity and regula-
tion, we compared the detection of autophosphorylation sites
in LRRK2 that fall between the amino terminal LRR and Roc
domain [LRRK2-Ser1292], the Roc domain [LRRK2-Thr1491]
and the carboxy terminal domain [LRRK2-Thr2483] to cellu-
lar site phosphorylation at Ser910, Ser935, Ser955, and Ser973.
We employed a recombinant preparation of full length LRRK2
purified from mammalian cells, which provides an advantage
over previous widely used preparations of recombinant forms
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FIGURE 4 | cAMP stimulation does not increase 14-3-3 binding in HEK
293 cells. (Ai–vi) Quantification of the phosphorylation levels at the cellular
sites (935, 955, 973), autophosphorylation site 1292, and 14-3-3 binding in
IBMX/FSK treatment relative to the DMSO treated control from (B). (B)
Representative blots of cellular site phosphorylation levels and
autophosphorylation at Ser1292 in the indicated GFP-LRRK2 mutants after
30min treatment with 50μM FSK/100μM IBMX. Stimulation of PKA activity
is verified by immunoblotting cell lysates with phospho-PKA substrate
antibody (Cell Signaling). Results are representative of 5 independent
experiments for WT, Gly2019Ser, and KD mutants, and 2 independent
experiments for the Arg1441Gly, Tyr1699Cys, and S910/935A mutants. The
ratio of phosphorylation over total GFP signal was normalized to WT DMSO,
error bars represent s.e.m. Statistical significance was assessed using the
(Continued)
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FIGURE 4 | Continued
One-Way ANOVA test combined with Tukey’s correction. ∗p ≤ 0.05.
Quantification of WT samples treated with DMSO and IBMX/FSK are
included in the graphs for reference, but were excluded in the statistical
analysis. (C) LRRK2 interaction with 14-3-3 in cells is diminished by
IBMX/FSK treatment. GFP or GFP-LRRK2 WT expressing HEK 293 T-REx
cells were treated with GNE1023 for 90min or 50μM FSK/100μM IBMX
for 30min, or in combination, then subjected to GFP Trap
immunoprecipitation. Immunoprecipitates were immunoblotted for 14-3-3
co-immunoprecipitation. (D) Lung epithelial alveolar A549 cells were
treated with 50μM FSK/100μM IBMX for 30min and endogenous
LRRK2 was immunoprecipitated and analyzed by immunoblot with
anti-LRRK2 (N241), anti-phospho-Ser935, anti-phospho-955,
anti-phospho-973 antibodies.
lacking the amino terminus (LRRK2 aa970–2527) and purified
from eukaryotic cells. This full length protein allows characteri-
zation of LRRK2 with all domains and their potential regulatory
action in place. We compared phosphorylation of LRRKtide
with autophosphorylation activity using pSer1292, pThr1491,
pThr1503, and pThr2484 antibodies in wild-type, Arg1441Cys
and Gly2019Ser mutants. LRRKtide and autophosphorylation
activity saturate in vitro and are predictive for outcomes in cells.
Out of these sites, only Ser1292 faithfully revealed active LRRK2
in vitro and in cells as an autophosphorylation site. Ile2012Thr
suppressed kinase activity against Ser1292 and Thr1491 and also
diminished the phosphorylation at the cellular sites.
Mutations Arg1441Cys, Arg1441Gly, Ala1442Pro, and
Tyr1699Cys in the Roc-COR domain could activate LRRK2
kinase through structural changes that limit GTPase activity,
prolonging the active state, leading to intramolecular stimulation
of kinase activity (Taymans et al., 2011; Tsika and Moore, 2013;
Liao et al., 2014). Recombinant Arg1441Cys exhibited increased
kinase activity against LRRKtide, 20% above wild-type levels.
Arg1441Cys, Arg1441Gly, Ala1442Pro, and Tyr1699Cys were
dephosphorylated at the cellular sites, but are hyperphospho-
rylated at Ser1292 in cells. We did observe a larger effect of
Tyr1699Cys on Ser1292 than previously described in Sheng et al.
Threonine 1491 was evaluated in the presence of ATP and we
found that this site revealed significant increase in kinase activity
from the Gly2019Ser mutation. Interestingly, in vitro autophos-
phorylation at Thr2483 also revealed significant increased kinase
activity from Arg1441Gly, and Gly2019Ser. The Tyr1699Cys
mutation suppressed autophosphorylation of Thr1491 similar
to what was observed for Thr1357 in Kamikawaji et al. (2013).
Interrogation of individual autophosphorylation sites reveals
different levels of mutation induced kinase activation, indicating
that several sites should be analyzed simultaneously because these
differences could be missed or misinterpreted by analysis of a
single autophosphorylation site or total phosphate incorporation.
Protective LRRK2 haplotypes have been reported for
Asn551Lys-Arg1398His-Leu1423Lys (Ross et al., 2011) and
Arg1398His (Heckman et al., 2014), which further supports
the notion that the amino terminus and the Roc-COR domain
could feed into the kinase domain activity. When the cellular
phosphorylation sites are mutated to unphosphorylatable Ala
residues, we observed that mutation of Ser910/935, Ser955, and
Ser973 to Ala did not affect intrinsic kinase activity in cells or
on isolated LRRK2. However, mutation of all of the cellular sites
to Ala trended toward slight increases in autophosphorylation
activity of LRRK2 at Ser1292, and 2483, which could reflect
regulatory activities of the amino terminal domain to the
kinase domain through structural changes in the enzyme or
through changes in subcellular localization. Increases in LRRK2
kinase activity from Arg1441Cys, Arg1441Gly, Ala1442Pro, and
Tyr1699Cys PD mutations is not linked to the induced dephos-
phorylation of the cellular sites because alanine substitutions
at serines 910/935/955/973 do not also increase LRRK2 kinase
activity.
The increased phosphorylation of Ser1292 compared to the
decreased phosphorylation of the cellular sites in Arg1441Cys,
Arg1441Gly, Ala1442Pro, and Tyr1699Cys mutants indicated that
there may be different phosphatases acting on these sites in addi-
tion to increasing the kinase activity of LRRK2. To understand the
class of phosphatase that act on Ser1292 compared to the cellular
sites, we utilized Calyculin A and Okadaic acid, pharmacological
inhibitors of PP1 and PP2, respectively. Ser1292 dephosphoryla-
tion is mediated by both CA and OA sensitive phosphatases, while
the cellular sites are sensitive to only CA sensitive phosphatases.
This supports the notion that indeed Ser1292 is dephospho-
rylated by a different phosphatase class than the cellular sites.
Ser1292 is a bona fide autophosphorylation site in vivo because
it does not become re-phosphorylated after inhibition of both
LRRK2 kinase and the phosphatase. This side-by-side compar-
ison also validates that Ser910/935/955/973 are not phosphory-
lated by LRRK2 like the direct autophosphorylation site Ser1292,
Thr1491, and Thr2483. Though the Ser1292 site is detected in
LRRK2 isolated from cells it is thought to be of low stoichiom-
etry with the total amount of LRRK2. The fact that Thr1491 or
Thr2483 were not detectable in cells may be due to low activ-
ity against these sites in cells or increased phosphatase activity
against these sites in cells. Alanine substitution of Ser1292 causes a
decrease in the cytoplasmic filaments and an increase in the cyto-
plasmic puncta caused by Arg1441Gly mutations (Sheng et al.,
2012). The different phosphatases that target both Ser1292 and
serines 910/935/955/973 are presumably more active on LRRK2
that has been inactivated through inhibition. In the future it
would be important to elucidate the Ser1292 phosphatase and/or
the phosphatase regulatory subunits that regulate the phosphatase
activity on LRRK2.
Phosphorylation of Ser1292 is a biochemical readout of
LRRK2 activity in cells and in vitro. LRRK2 inhibitor induced
dephosphorylation of LRRK2 cellular sites Ser910/935/955/973
and Ser1292 are observed at similar IC50s, indicating that both
are measures of activity. We were also able to detect increased
Ser1292 activity in a Gly2019Ser heterozygous patient derived
lymphoblastoid culture, and that Ser935/955/973 as well as
Ser1292 were efficiently dephosphorylated in these cells upon
GNE treatment, suggesting that Ser1292 can be employed as a
measure of LRRK2 activity in patients. High levels of LRRK2
expression in the periphery and responsiveness of the cellu-
lar sites and Ser1292 to specific LRRK2 inhibitors provides a
tractable patient sample source to ascertain and analyze LRRK2
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FIGURE 5 | Serine 1292 is regulated by Calyculin A and Okadaic acid
sensitive phosphatases. Stable-inducible HEK 293 T-REx cell lines
overexpressing Gly2019Ser or Arg1441Gly LRRK2 mutation were treated
with Okadaic acid or Calyculin A alone, or combined with GNE1023. (A)
Representative blots of phosphorylation levels in Gly2019Ser and Arg1441Gly
LRRK2 mutation line. (B–E) Quantification of anti-phospho-Ser935,
anti-phospho-955, anti-phospho-973, and anti-phospho-1292 phosphorylation
levels relative to the DMSO treated control of each mutant. The immunoblots
shown are representative of three independent experiments. Statistical
significance of Ser1292 stimulation with CA and OA was assessed using a
one sample t-test set to the hypothetical value of 1, +p ≤ 0.05. An ordinary
One-Way ANOVA test combined with Dunnett’s correction for multiple
testing was used to assess the ability of CA and OA to overcome GNE
inhibition ∗p ≤ 0.05 on connecting bars, n.s., not significant. DMSO control
treated samples were not included in the ANOVA test and treatments were
compared to GNE (alone) treated samples.
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modification in longitudinal studies or as a surrogate marker for
targeting LRRK2 during inhibitor based trials.
We next explored the effects of modulating cAMP induced
PKA activity on LRRK2 autocatalytic activity and cellular phos-
phorylation. We found that Forskolin/IBMX treatment resulted
in a consistent diminution of both the cellular sites and
Ser1292, and no change in 14-3-3 binding. Though contra-
dictory to the report in Muda et al. (2014), these data are
consistent with previous reports that loss of either Ser910 or
Ser935 phosphorylation does not change kinase activity but does
result is loss of 14-3-3 binding in cells and in overlay far-
western assays. Furthermore, treatment of cells with H89, a PKA
inhibitor does not reduce LRRK2 phosphorylation at Ser935
(Hermanson et al., 2012).
We characterized three autoregulatory phosphosites [Ser1292,
Thr1491, and Thr2483] alongside the cellular phosphorylation
sites [Ser910/935/955/973] to reveal true differences in how
pathogenic PD mutations affect the activity and phosphorylation
status of LRRK2. The kinase domain of LRRK2 is peculiarly
packed amongst several structural and enzymatic domains that
influence the kinase activity of LRRK2. Figure 6A illustrates the
domain structure of LRRK2, along with the position of PDmuta-
tions, autophosphorylation sites and the cellular phosphorylation
sites. Roc-CORmutations can increase the kinase activity through
intramolecular effects (Figure 6A1) as indicated by autophospho-
rylation sites Figure 6A2. Figure 6B depicts the proposed regula-
tion of LRRK2 phosphorylation at the cellular phosphorylation
sites and Ser1292 by upstream kinases (Figure 6B3) and phos-
phatases (Figure 6B4), which could be up and down-regulated
by LRRK2, respectively. At the same time, Roc-COR mutations
enhance the dephosphorylation of LRRK2 at the cellular sites
through increased interaction with phosphatases, Figure 6B5.
Ser1292 is dephosphorylated by Okadaic acid and Calyculin
A sensitive phosphatases, Figure 6B6. LRRK2 autophosphory-
lates each site differently dependent on mutation and these
autophosphorylation sites indicate LRRK2 activity different from
FIGURE 6 | Model of intramolecular and intermolecular LRRK2
regulation. The LRRK2 structure with PD associated mutants highlighted
in red (pathogenic) and risk factors in gray. Cellular phosphorylation sites
are highlighted in blue and autophosphorylation sites are in black. (A1)
The intramolecular regulation of the PD associated mutants in the
Roc-COR domain and the carboxy terminus on LRRK2 kinase activity.
(A2) Differential effects of the PD mutations can be detected through
the autophosphorylation sites Ser1292, Thr1491, and Ser2483. (B3,B4)
Kinases and phosphatases contribute to the intermolecular regulation of
LRRK2 and their effects can be demonstrated through cellular
phosphorylation sites and autophosphorylation sites. (B5) Roc-COR
mutations enhance the dephosphorylation of LRRK2 at the cellular sites
through increased interaction with phosphatases. Ser1292 is
dephosphorylated by Okadaic acid and Calyculin A sensitive phosphatases,
(B6) Mutations within the Roc-COR allow for increased interactions with
phosphatases and this decreases the cellular phosphorylation levels.
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the cellular sites. Further investigation of the phosphoregulation
of LRRK2 will continue to provide novel insight into the normal
activities of the enzyme as well as how PDmutations may disrupt
enzyme function.
ACKNOWLEDGMENTS
We would like to thank Professor Dario R. Alessi for gener-
ous provision of plasmids. We would like to thank Dr. Andrew
B. West for kindly sharing antibodies. We would like to thank
Genentech for the generous provision of antibodies and small
molecule LRRK2 inhibitors. We would also like to acknowledge
the Michael J. Fox Foundation for antibody generation efforts
of the Antibodies Working Group of which the corresponding
author is a member. We are gracious for critical reading of the
manuscript by Dr. Tyler Molitor and Dr. Quyen Hong. Funding
was provided by the Michael J. Fox Foundation and the benev-
olence of the Brin/Wojcicki Foundation to R. Jeremy Nichols. R.
Jeremy Nichols is a consultant for ThermoFisher.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: http://www.frontiersin.org/journal/10.3389/fnmol.2014.
00054/abstract
REFERENCES
Adams, J. R., Van Netten, H., Schulzer, M., Mak, E., McKenzie, J., Strongosky, A.,
et al. (2005). PET in LRRK2 mutations: comparison to sporadic Parkinson’s
disease and evidence for presymptomatic compensation. Brain 128, 2777–2785.
doi: 10.1093/brain/awh607
Alegre-Abarrategui, J., Christian, H., Lufino, M. M., Mutihac, R., Venda, L. L.,
Ansorge, O., et al. (2009). LRRK2 regulates autophagic activity and localizes to
specific membrane microdomains in a novel human genomic reporter cellular
model. Hum. Mol. Genet. 18, 4022–4034. doi: 10.1093/hmg/ddp346
Baptista, M. A., Dave, K. D., Frasier, M. A., Sherer, T. B., Greeley, M., Beck, M.
J., et al. (2013). Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to
progressive abnormal phenotypes in peripheral organs. PLoS ONE 8:e80705.
doi: 10.1371/journal.pone.0080705
Biosa, A., Trancikova, A., Civiero, L., Glauser, L., Bubacco, L., Greggio, E., et al.
(2013). GTPase activity regulates kinase activity and cellular phenotypes of
Parkinson’s disease-associated LRRK2. Hum. Mol. Genet. 22, 1140–1156. doi:
10.1093/hmg/dds522
Biskup, S., and West, A. B. (2009). Zeroing in on LRRK2-linked pathogenic
mechanisms in Parkinson’s disease. Biochim. Biophys. Acta 1792, 625–633. doi:
10.1016/j.bbadis.2008.09.015
Daniels, V., Vancraenenbroeck, R., Law, B. M., Greggio, E., Lobbestael, E., Gao, F.,
et al. (2011). Insight into the mode of action of the LRRK2 Y1699C pathogenic
mutant. J. Neurochem. 116, 304–315. doi: 10.1111/j.1471-4159.2010.07105.x
Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., et al. (2011).
Characterization of a selective inhibitor of the Parkinson’s disease kinase
LRRK2. Nat. Chem. Biol. 7, 203–205. doi: 10.1038/nchembio.538
Di Fonzo, A., Rohe, C. F., Ferreira, J., Chien, H. F., Vacca, L., Stocchi, F., et al.
(2005). A frequent LRRK2 gene mutation associated with autosomal dominant
Parkinson’s disease. Lancet 365, 412–415. doi: 10.1016/S0140-6736(05)17829-5
Di Fonzo, A., Tassorelli, C., De Mari, M., Chien, H. F., Ferreira, J., Rohe,
C. F., et al. (2006). Comprehensive analysis of the LRRK2 gene in sixty
families with Parkinson’s disease. Eur. J. Hum. Genet. 14, 322–331. doi:
10.1038/sj.ejhg.5201539
Doggett, E. A., Zhao, J., Mork, C. N., Hu, D., and Nichols, R. J. (2012).
Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson’s
disease mutations and LRRK2 pharmacological inhibition. J. Neurochem. 120,
37–45. doi: 10.1111/j.1471-4159.2011.07537.x
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G.,
Kieburtz, K., et al. (2007). Projected number of people with Parkinson disease
in the most populous nations, 2005 through 2030. Neurology 68, 384–386. doi:
10.1212/01.wnl.0000247740.47667.03
Estrada, A. A., Liu, X., Baker-Glenn, C., Beresford, A., Burdick, D. J., Chambers,
M., et al. (2012). Discovery of highly potent, selective, and brain-penetrable
leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J. Med. Chem.
55, 9416–9433. doi: 10.1021/jm301020q
Farrer, M., Stone, J., Mata, I. F., Lincoln, S., Kachergus, J., Hulihan, M., et al.
(2005). LRRK2 mutations in Parkinson disease. Neurology 65, 738–740. doi:
10.1212/01.WNL.0000169023.51764.b0
Gloeckner, C. J., Boldt, K., Von Zweydorf, F., Helm, S., Wiesent, L., Sarioglu,
H., et al. (2010). Phosphopeptide analysis reveals two discrete clusters of
phosphorylation in the N-terminus and the Roc domain of the Parkinson-
disease associated protein kinase LRRK2. J. Proteome Res. 9, 1738–1745. doi:
10.1021/pr9008578
Greene, I. D., Mastaglia, F., Meloni, B. P., West, K. A., Chieng, J., Mitchell, C.
J., et al. (2014). Evidence that the LRRK2 ROC domain Parkinson’s disease-
associated mutants A1442P and R1441C exhibit increased intracellular degra-
dation. J. Neurosci. Res. 92, 506–516. doi: 10.1002/jnr.23331
Greggio, E., and Cookson, M. R. (2009). Leucine-rich repeat kinase 2 muta-
tions and Parkinson’s disease: three questions. ASN Neuro 1, e00002. doi:
10.1042/AN20090007
Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich,
A., et al. (2006). Kinase activity is required for the toxic effects of
mutant LRRK2/dardarin. Neurobiol. Dis. 23, 329–341. doi: 10.1016/j.nbd.2006.
04.001
Greggio, E., Zambrano, I., Kaganovich, A., Beilina, A., Taymans, J. M., Daniels,
V., et al. (2008). The Parkinson disease-associated leucine-rich repeat kinase 2
(LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J. Biol.
Chem. 283, 16906–16914. doi: 10.1074/jbc.M708718200
Haugarvoll, K., Rademakers, R., Kachergus, J. M., Nuytemans, K., Ross, O.
A., Gibson, J. M., et al. (2008). Lrrk2 R1441C parkinsonism is clini-
cally similar to sporadic Parkinson disease. Neurology 70, 1456–1460. doi:
10.1212/01.wnl.0000304044.22253.03
Haugarvoll, K., and Wszolek, Z. K. (2009). Clinical features of LRRK2 parkinson-
ism. Parkinsonism Relat. Disord. 15(Suppl. 3), S205–S208. doi: 10.1016/S1353-
8020(09)70815-6
Healy, D. G., Falchi, M., O’Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., et al.
(2008). Phenotype, genotype, and worldwide genetic penetrance of LRRK2-
associated Parkinson’s disease: a case-control study. Lancet Neurol. 7, 583–590.
doi: 10.1016/S1474-4422(08)70117-0
Heckman, M. G., Elbaz, A., Soto-Ortolaza, A. I., Serie, D. J., Aasly, J. O., Annesi, G.,
et al. (2014). The protective effect of LRRK2 p.R1398H on risk of Parkinson’s
disease is independent of MAPT and SNCA variants. Neurobiol. Aging 35, 266
e265–266 e214. doi: 10.1016/j.neurobiolaging.2013.07.013
Hermanson, S. B., Carlson, C. B., Riddle, S. M., Zhao, J., Vogel, K. W., Nichols, R. J.,
et al. (2012). Screening for novel LRRK2 inhibitors using a high-throughput TR-
FRET cellular assay for LRRK2 Ser935 phosphorylation. PLoS ONE 7:e43580.
doi: 10.1371/journal.pone.0043580
Herzig, M. C., Kolly, C., Persohn, E., Theil, D., Schweizer, T., Hafner, T., et al.
(2011). LRRK2 protein levels are determined by kinase function and are cru-
cial for kidney and lung homeostasis in mice. Hum. Mol. Genet. 20, 4209–4223.
doi: 10.1093/hmg/ddr348
Huang, Y., Halliday, G. M., Vandebona, H., Mellick, G. D., Mastaglia, F., Stevens,
J., et al. (2007). Prevalence and clinical features of common LRRK2 muta-
tions in Australians with Parkinson’s disease. Mov. Disord. 22, 982–989. doi:
10.1002/mds.21477
Ishihara, L., Warren, L., Gibson, R., Amouri, R., Lesage, S., Durr, A., et al. (2006).
Clinical features of Parkinson disease patients with homozygous leucine-
rich repeat kinase 2 G2019S mutations. Arch. Neurol. 63, 1250–1254. doi:
10.1001/archneur.63.9.1250
Jaleel, M., Nichols, R. J., Deak, M., Campbell, D. G., Gillardon, F., Knebel, A., et al.
(2007). LRRK2 phosphorylates moesin at threonine-558: characterization of
how Parkinson’s disease mutants affect kinase activity. Biochem. J. 405, 307–317.
doi: 10.1042/BJ20070209
Jorgensen, N. D., Peng, Y., Ho, C. C., Rideout, H. J., Petrey, D., Liu, P., et al. (2009).
The WD40 domain is required for LRRK2 neurotoxicity. PLoS ONE 4:e8463.
doi: 10.1371/journal.pone.0008463
Kamikawaji, S., Ito, G., and Iwatsubo, T. (2009). Identification of the autophospho-
rylation sites of LRRK2. Biochemistry 48, 10963–10975. doi: 10.1021/bi9011379
Frontiers in Molecular Neuroscience www.frontiersin.org June 2014 | Volume 7 | Article 54 | 13
Reynolds et al. LRRK2 phosphoregulation
Kamikawaji, S., Ito, G., Sano, T., and Iwatsubo, T. (2013). Differential effects of
familial parkinson mutations in LRRK2 revealed by a systematic analysis of
autophosphorylation. Biochemistry 52, 6052–6062. doi: 10.1021/bi400596m
Kett, L. R., Boassa, D., Ho, C. C., Rideout, H. J., Hu, J., Terada, M., et al. (2011).
LRRK2 Parkinson disease mutations enhance its microtubule association.Hum.
Mol. Genet. 21, 890–899. doi: 10.1093/hmg/ddr526
Lesage, S., Patin, E., Condroyer, C., Leutenegger, A. L., Lohmann, E., Giladi, N.,
et al. (2010). Parkinson’s disease-related LRRK2 G2019S mutation results from
independent mutational events in humans. Hum. Mol. Genet. 19, 1998–2004.
doi: 10.1093/hmg/ddq081
Li, X., Moore, D. J., Xiong, Y., Dawson, T. M., and Dawson, V. L.
(2010). Reevaluation of phosphorylation sites in the Parkinson disease-
associated leucine-rich repeat kinase 2. J. Biol. Chem. 285, 29569–29576. doi:
10.1074/jbc.M110.127639
Li, X., Wang, Q. J., Pan, N., Lee, S., Zhao, Y., Chait, B. T., et al. (2011).
Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by com-
mon mutations of familial Parkinson’s disease. PLoS ONE 6:e17153. doi:
10.1371/journal.pone.0017153
Liao, J., Wu, C. X., Burlak, C., Zhang, S., Sahm, H., Wang, M., et al. (2014).
Parkinson disease-associated mutation R1441H in LRRK2 prolongs the “active
state” of its GTPase domain. Proc. Natl. Acad. Sci. U.S.A. 111, 4055–4060. doi:
10.1073/pnas.1323285111
Lill, C.M., Roehr, J. T., McQueen,M. B., Kavvoura, F. K., Bagade, S., Schjeide, B.M.,
et al. (2012). Comprehensive research synopsis and systematic meta-analyses in
Parkinson’s disease genetics: the PDGene database. PLoS Genet. 8:e1002548. doi:
10.1371/journal.pgen.1002548
Lobbestael, E., Zhao, J., Rudenko, I. N., Beylina, A., Gao, F., Wetter, J., et al.
(2013). Identification of protein phosphatase 1 as a regulator of the LRRK2
phosphorylation cycle. Biochem. J. 456, 119–128. doi: 10.1042/BJ20121772
Muda, K., Bertinetti, D., Gesellchen, F., Hermann, J. S., Von Zweydorf, F., Geerlof,
A., et al. (2014). Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA
phosphorylation of LRRK2 and disrupts its interaction with 14-3-3. Proc. Natl.
Acad. Sci. U.S.A. 111, E34–E43. doi: 10.1073/pnas.1312701111
Nichols, R. J., Dzamko, N., Hutti, J. E., Cantley, L. C., Deak, M., Moran, J., et al.
(2009). Substrate specificity and inhibitors of LRRK2, a protein kinase mutated
in Parkinson’s disease. Biochem. J. 424, 47–60. doi: 10.1042/BJ20091035
Nichols, R. J., Dzamko, N., Morrice, N. A., Campbell, D. G., Deak, M., Ordureau,
A., et al. (2010). 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson’s
disease-associated mutations and regulates cytoplasmic localization. Biochem. J.
430, 393–404. doi: 10.1042/BJ20100483
Paisan-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simon, J., Van Der Brug, M.,
et al. (2004). Cloning of the gene containingmutations that cause PARK8-linked
Parkinson’s disease. Neuron 44, 595–600. doi: 10.1016/j.neuron.2004.10.023
Paisan-Ruiz, C., Nath, P., Washecka, N., Gibbs, J. R., and Singleton, A. B. (2008).
Comprehensive analysis of LRRK2 in publicly available Parkinson’s disease
cases and neurologically normal controls. Hum. Mutat. 29, 485–490. doi:
10.1002/humu.20668
Parisiadou, L., Yu, J., Sgobio, C., Xie, C., Liu, G., Sun, L., et al. (2014). LRRK2
regulates synaptogenesis and dopamine receptor activation throughmodulation
of PKA activity. Nat. Neurosci. 17, 367–376. doi: 10.1038/nn.3636
Pungaliya, P. P., Bai, Y., Lipinski, K., Anand, V. S., Sen, S., Brown, E. L., et al. (2010).
Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2)
consensus phosphorylation motif. PLoS ONE 5:e13672. doi: 10.1371/jour-
nal.pone.0013672
Reed, S. E., Staley, E. M., Mayginnes, J. P., Pintel, D. J., and Tullis, G. E. (2006).
Transfection of mammalian cells using linear polyethylenimine is a simple
and effective means of producing recombinant adeno-associated virus vectors.
J. Virol. Methods 138, 85–98. doi: 10.1016/j.jviromet.2006.07.024
Ross, O. A., Soto-Ortolaza, A. I., Heckman, M. G., Aasly, J. O., Abahuni, N.,
Annesi, G., et al. (2011). Association of LRRK2 exonic variants with suscepti-
bility to Parkinson’s disease: a case-control study. Lancet Neurol. 10, 898–908.
doi: 10.1016/S1474-4422(11)70175-2
Ross, O. A., Toft, M., Whittle, A. J., Johnson, J. L., Papapetropoulos, S., Mash, D.
C., et al. (2006). Lrrk2 and Lewy body disease. Ann. Neurol. 59, 388–393. doi:
10.1002/ana.20731
Ross, O. A., Wu, Y. R., Lee, M. C., Funayama, M., Chen, M. L., Soto, A. I., et al.
(2008). Analysis of Lrrk2 R1628P as a risk factor for Parkinson’s disease. Ann.
Neurol. 64, 88–92. doi: 10.1002/ana.21405
Rudenko, I. N., Kaganovich, A., Hauser, D. N., Beylina, A., Chia, R., Ding, J.,
et al. (2012). The G2385R variant of leucine-rich repeat kinase 2 associated
with Parkinson’s disease is a partial loss-of-function mutation. Biochem. J. 446,
99–111. doi: 10.1042/BJ20120637
Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., et al. (2009).
Genome-wide association study identifies common variants at four loci as
genetic risk factors for Parkinson’s disease. Nat. Genet. 41, 1303–1307. doi:
10.1038/ng.485
Sheng, Z., Zhang, S., Bustos, D., Kleinheinz, T., Le Pichon, C. E., Dominguez, S.
L., et al. (2012). Ser1292 autophosphorylation is an indicator of LRRK2 kinase
activity and contributes to the cellular effects of PD mutations. Sci. Transl. Med.
4, 164ra161. doi: 10.1126/scitranslmed.3004485
Simon-Sanchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D.,
et al. (2009). Genome-wide association study reveals genetic risk underlying
Parkinson’s disease. Nat. Genet. 41, 1308–1312. doi: 10.1038/ng.487
Skipper, L., Li, Y., Bonnard, C., Pavanni, R., Yih, Y., Chua, E., et al. (2005).
Comprehensive evaluation of common genetic variation within LRRK2 reveals
evidence for association with sporadic Parkinson’s disease.Hum. Mol. Genet. 14,
3549–3556. doi: 10.1093/hmg/ddi376
Sossi, V., De La Fuente-Fernandez, R., Nandhagopal, R., Schulzer, M., McKenzie, J.,
Ruth, T. J., et al. (2010). Dopamine turnover increases in asymptomatic LRRK2
mutations carriers. Mov. Disord. 25, 2717–2723. doi: 10.1002/mds.23356
Tan, E. K., Tan, L. C., Lim, H. Q., Li, R., Tang, M., Yih, Y., et al. (2008). LRRK2
R1628P increases risk of Parkinson’s disease: replication evidence. Hum. Genet.
124, 287–288. doi: 10.1007/s00439-008-0544-2
Taymans, J. M., Vancraenenbroeck, R., Ollikainen, P., Beilina, A., Lobbestael, E., De
Maeyer, M., et al. (2011). LRRK2 kinase activity is dependent on LRRK2 GTP
binding capacity but independent of LRRK2 GTP binding. PLoS ONE 6:e23207.
doi: 10.1371/journal.pone.0023207
Tsika, E., and Moore, D. J. (2013). Contribution of GTPase activity to
LRRK2-associated Parkinson disease. Small GTPases 4, 164–170. doi:
10.4161/sgtp.25130
Webber, P. J., Smith, A. D., Sen, S., Renfrow, M. B., Mobley, J. A., and West, A.
B. (2011). Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2)
GTPase domain modifies kinase and GTP-binding activities. J. Mol. Biol. 412,
94–110. doi: 10.1016/j.jmb.2011.07.033
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., et al.
(2005). Parkinson’s disease-associated mutations in leucine-rich repeat kinase
2 augment kinase activity. Proc. Natl. Acad. Sci. U.S.A. 102, 16842–16847. doi:
10.1073/pnas.0507360102
West, A. B., Moore, D. J., Choi, C., Andrabi, S. A., Li, X., Dikeman, D., et al. (2007).
Parkinson’s disease-associatedmutations in LRRK2 link enhanced GTP-binding
and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16, 223–232. doi:
10.1093/hmg/ddl471
Whaley, N. R., Uitti, R. J., Dickson, D. W., Farrer, M. J., and Wszolek, Z. K. (2006).
Clinical and pathologic features of families with LRRK2-associated Parkinson’s
disease. J. Neural Transm. Suppl. 70, 221–229. doi: 10.1007/978-3-211-
45295-0_34
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., et al. (2004).
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomor-
phic pathology. Neuron 44, 601–607. doi: 10.1016/j.neuron.2004.11.005
Conflict of Interest Statement: R. Jeremy Nichols is a consultant for Thermo
Fisher. Steve M. Riddle and Connie S. Lebakken are both employees of Thermo
Fisher. Thermo Fisher had no role in the design or implementation of the study.
Received: 30 March 2014; accepted: 28 May 2014; published online: 24 June 2014.
Citation: Reynolds A, Doggett EA, Riddle SM, Lebakken CS and Nichols RJ (2014)
LRRK2 kinase activity and biology are not uniformly predicted by its autophosphoryla-
tion and cellular phosphorylation site status. Front. Mol. Neurosci. 7:54. doi: 10.3389/
fnmol.2014.00054
This article was submitted to the journal Frontiers in Molecular Neuroscience.
Copyright © 2014 Reynolds, Doggett, Riddle, Lebakken and Nichols. This is an open-
access article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Molecular Neuroscience www.frontiersin.org June 2014 | Volume 7 | Article 54 | 14
